Patents Assigned to Gilead Sciences, Inc.
  • Therapeutic compositions for treatment of human immunodeficiency virus
    Patent number: 11744802
    Abstract: A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: September 5, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Benjamin Micah Collman, Lei Hong, Joanna M. Koziara
  • FXR (NR1H4) modulating compounds
    Patent number: 11739065
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: November 29, 2021
    Date of Patent: August 29, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors
    Patent number: 11738013
    Abstract: Provided are methods for treating hepatitis B virus infections by administering a NS5A inhibitor, NS5B inhibitor, a NS3 inhibitor, or combinations thereof.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: August 29, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Anuj Gaggar, G. Mani Subramanian
  • Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
    Patent number: 11739101
    Abstract: The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.
    Type: Grant
    Filed: May 5, 2021
    Date of Patent: August 29, 2023
    Assignees: Nurix Therapeutics, Inc., Gilead Sciences, Inc.
    Inventors: Hunter P. Shunatona, Galen Paul Shearn-Nance, Scott A. Mitchell, John Buell
  • HBV vaccines and methods treating HBV
    Patent number: 11730808
    Abstract: Provided are HBV immunogenic polypeptides, polynucleotides encoding such polypeptides, vectors expressing such immunogenic polypeptides for use in eliciting an immune response against HBV; pharmaceutical and immunogenic compositions and kits comprising such polypeptides, polynucleotides or vectors, and methods of use in treating and/or preventing HBV.
    Type: Grant
    Filed: October 3, 2022
    Date of Patent: August 22, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Scott J. Balsitis, Sarah M. Ahmadi-Erber, Timo Schippers, Sarah Schmidt
  • Prodrugs of 4?-C-substituted-2-halo-2?- deoxyadenosine nucleosides and methods of making and using the same
    Patent number: 11718637
    Abstract: The present disclosure provides prodrugs of 4?-C-substituted-2-halo-2?-deoxyadenoside nucleosides, and compositions, methods, and kits thereof. Such compounds can be useful for treating viral infections including, but not limited to, human immunodeficiency virus.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: August 8, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Daniel H. Byun, Byoung-Kwon Chun, Michael O. Clarke, Petr Jansa, Richard L. Mackman, Devan Naduthambi, Neil H. Squires
  • IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF
    Publication number: 20230242508
    Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zink Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.
    Type: Application
    Filed: December 20, 2022
    Publication date: August 3, 2023
    Applicant: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Zhimin Du, Musong Kim, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani
  • Combination formulation of two antiviral compounds
    Patent number: 11707479
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: July 25, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • GLP-1R modulating compounds
    Patent number: 11702404
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: July 18, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Michael Graupe, Chao-I Hung, Kavoos Kolahdouzan, Scott D. Schroeder, Nathan D. Shapiro, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
    Patent number: 11701372
    Abstract: The present disclosure provides pharmaceutical formulations of the compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, and an aqueous vehicle. The pharmaceutical formulations of the disclosure are useful in treatment and prevention of viral infections in subjects in need thereof and are for administration by inhalation.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: July 18, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Scott Ellis, Davin S. Rautiola, Dustin S. Siegel, Maria M. Toteva, Adelle A. Vandersteen
  • Thiadiazole IRAK4 inhibitors
    Patent number: 11702414
    Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: July 18, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen Ammann, Elizabeth M. Bacon, Gediminas Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Marilyn Ndukwe, Marina Shatskikh, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • LPA receptor antagonists and uses thereof
    Patent number: 11702407
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: July 18, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Kin S. Yang, Anna Zagorska
  • Tetracyclic compounds and uses thereof
    Patent number: 11697652
    Abstract: The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: July 11, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Lan Jiang, David W. Lin, Michael L. Mitchell, Ezra Roberts, Gregg M. Schwarzwalder
  • Methods of preparing carbanucleosides using amides
    Patent number: 11697666
    Abstract: The present disclosure describes methods of preparing carbanucleosides.
    Type: Grant
    Filed: April 14, 2022
    Date of Patent: July 11, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Trevor C. Johnson, Matthew Kraft, Marshall D. Young
  • Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
    Patent number: 11692038
    Abstract: Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: July 4, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Lara Lewis McGrath, Fabien Dépis, Changyun Hu, Leonard G. Presta, Joshua Adam Buggé
  • Capsid inhibitors for the prevention of HIV
    Patent number: 11685728
    Abstract: The present disclosure provides methods of preventing HIV in a subject, comprising administering to the subject a therapeutically effective amount of a compounds of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. Methods of reducing the risk of acquiring HIV (e.g., HIV-1 and/or HIV-2) are also provided.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: June 27, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Elena Bekerman, Wade S. Blair, Anna Chiu, Tomas Cihlar, Dana J. Levine, Winston C. Tse, Stephen R. Yant, Jim X. Zheng
  • Capsid inhibitors for the treatment of HIV
    Patent number: 11680064
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: June 20, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Chienhung Chou, Darryl Kato, Scott E. Lazerwith, John O. Link, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • Antiviral pyrazolopyridinone compounds
    Patent number: 11667613
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: June 6, 2023
    Assignees: Novartis AG, Gilead Sciences, Inc.
    Inventors: Zef Konst, Yipin Lu, Robert Joseph Moreau, Naomi Samadara Rajapaksa, Galen Shearn-Nance, David Charles Tully, Michael Robert Turner, Joseph Michael Young, Qian Zhao, Britton K. Corkey, Samuel E. Metobo
  • MCL1 inhibitors
    Patent number: 11667652
    Abstract: The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: June 6, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, QingMing Zhu
  • Methods for treating SARS CoV-2 infections
    Patent number: 11660307
    Abstract: Provided are methods for treating 2019-nCoV virus (SARS-CoV-2) infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: May 30, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Tomas Cihlar, Anuoluwapo Osinusi, Danielle L. Porter